Doxepin Hydrochloride Patent Expiration
Doxepin Hydrochloride is Used for treating insomnia. It was first introduced by Pfizer Laboratories Div Pfizer Inc
Doxepin Hydrochloride Patents
Given below is the list of patents protecting Doxepin Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Silenor | US8513299 | Methods of using low-dose doxepin for the improvement of sleep | Sep 07, 2030 | Currax |
| Silenor | US9532971 | Low-dose doxepin formulations and methods of making and using the same | Jun 01, 2029 | Currax |
| Silenor | US9107898 | Methods of using low-dose doxepin for the improvement of sleep | May 01, 2028 | Currax |
| Silenor | US10548871 | Low-dose doxepin formulations and methods of making and using the same | Apr 11, 2028 | Currax |
| Silenor | US11096920 | Low-dose doxepin formulations and methods of making and using the same | Apr 11, 2028 | Currax |
| Silenor | US9907780 | Low-dose doxepin formulations and methods of making and using the same | Apr 11, 2028 | Currax |
| Silenor | US11234954 | Low-dose doxepin for treatment of sleep disorders in elderly patients | Jan 18, 2028 | Currax |
| Silenor | US7915307 | Methods of improving the pharmacokinetics of doxepin | Aug 24, 2027 | Currax |
| Silenor | US10653660 | Methods of improving the pharmacokinetics of doxepin | Jul 20, 2027 | Currax |
| Silenor | US11110074 | Methods of improving the pharmacokinetics of doxepin | Jul 20, 2027 | Currax |
| Silenor | US9572814 | Methods of improving the pharmacokinetics of doxepin | Jul 20, 2027 | Currax |
| Silenor | US10238620 | Methods of using low-dose doxepin for the improvement of sleep | May 18, 2027 | Currax |
| Silenor | US10653662 | Methods of using low-dose doxepin for the improvement of sleep | May 18, 2027 | Currax |
| Silenor | US12083090 | Methods of using low-dose doxepin for the improvement of sleep | May 18, 2027 | Currax |
| Silenor | US9486437 | Methods of using low-dose doxepin for the improvement of sleep | May 18, 2027 | Currax |
| Silenor | US9861607 | Methods of using low-dose doxepin for the improvement of sleep | May 18, 2027 | Currax |
| Silenor | US6211229 | Treatment of transient and short term insomnia |
Feb 17, 2020
(Expired) | Currax |
| Silenor | US5585115 | Pharmaceutical excipient having improved compressability |
Jan 09, 2015
(Expired) | Currax |
| Silenor | US5725884 | Pharmaceutical excipient having improved compressibility |
Jan 09, 2015
(Expired) | Currax |
| Silenor | US5866166 | Pharmaceutical excipient having improved compressibility |
Jan 09, 2015
(Expired) | Currax |
| Silenor | US5948438 | Pharmaceutical formulations having improved disintegration and/or absorptivity |
Jan 09, 2015
(Expired) | Currax |
| Silenor | US6103219 | Pharmaceutical excipient having improved compressibility |
Jan 09, 2015
(Expired) | Currax |
| Silenor | US6217909 | Pharmaceutical excipient having improved compressibility |
Jan 09, 2015
(Expired) | Currax |
| Silenor | US5502047 | Treatment for insomnia |
Mar 26, 2013
(Expired) | Currax |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Doxepin Hydrochloride's patents.
Latest Legal Activities on Doxepin Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Doxepin Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Yr, Small Entity | 19 Jun, 2024 | US9532971 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 24 Apr, 2024 | US9486437 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 01 Nov, 2023 | US10653660 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 01 Nov, 2023 | US10653662 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 19 Jul, 2023 | US10548871 |
| Payment of Maintenance Fee, 8th Yr, Small Entity | 01 Feb, 2023 | US9107898 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 14 Sep, 2022 | US10238620 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 14 Sep, 2022 | US7915307(Litigated) |
| Patent Issue Date Used in PTA Calculation Critical
| 01 Feb, 2022 | US11234954 |
| Recordation of Patent Grant Mailed Critical
| 01 Feb, 2022 | US11234954 |
Doxepin Hydrochloride's Family Patents
